Top

Published in:

01-05-2006 | Original Article

Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models

Authors: Kaname Yamamoto, Shinichi Yoshino, Goukei Shue, Masakazu Nagashima

Published in: Rheumatology International | Issue 7/2006

Abstract

This study was conducted to identify bone resorption and anti-inflammatory effects with intermittent cyclical etidronate therapy (ICET) in patients with rheumatoid arthritis, and anti-inflammatory effect of etidronate in vitro. We compared bone mineral density (BMD), urinary deoxypyridinoline (DPD) level, bone alkaline phosphatase (BAP) level and Larsen damage scores between the ICET and the non-ICET groups for 3 years. The levels of interleukin-6 (IL-6), prostaglandin E₂ (PGE₂), substance P and vascular endothelial growth factor (VEGF) in synovial cells from arthritis models were measured following the addition of etidronate. In the ICET group, BMD and BAP levels increased. Urinary DPD level and the Larsen damage score were significantly lower than that in the non-ICET group. In the in vitro study, the production of IL-6, PGE₂, substance P and VEGF were inhibited in a dose-dependent manner. Bone resorption and destruction inhibition effect of etidronate remained for 3 years. In vitro study showed that the production of inflammatory cytokines and an angiogenesis factor were inhibited.

Bromley M, Wooley DE (1984) Chondroclasts and osteoclasts at subchondral sites of erosion in rheumatoid joint. Arthritis Rheum 27:968–975PubMedCrossRef

Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR (1998) Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 152:943–951PubMed

Pearson CM (1956) Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 91:95–101PubMed

Pearson CM, Wood FD (1963) Studies of arthritis and other lesions induced in rats by the injection of mycobacterial adjuvant. VII. Pathologic details of the arthritis and spondylitis. Am J Pathol 42:73–95PubMed

Inoue T, Kusida K, Miyamoto S, Sumi Y, Orimo H, Yamashita G (1983) Quantitative assessment of bone density on X-ray picture. J Jpn Orthop 57:1923–1936

Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and released conditions by standard reference films. Acta Radiol Diagn 18:481–491

Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S (2003) Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol 30:474–479PubMed

Shimizu S, Shiozawa S, Shiozawa K, Imura S, Fujita T (1985) Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum 28:25–31PubMedCrossRef

Gough AKS, Peel NFA, Eastell R, Holder RL, Lilley J, Emery P (1994) Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 53:14–17PubMed

10.

Haugeberg G, Uhlig T, Falch J, Halse JI, Kvien TK (2004) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Results from 394 patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 3:522–530

11.

Suzuki Y, Tanihara M, Ichikawa Y, Osanai A, Nakagawa M, Ide M, Mizushima Y (1994) Periarticular osteopenia in adjuvant-induced arthritis: role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells. Ann Rheum Dis 54:484–490

12.

Matsuno H, Sawai T, Nezuka T, Uzuki M, Tsuji H, Nishimoto N, Yoshizaki K (1998) Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody; use of rheumatoid arthritis tissue implants in SCID mouse model. Arthritis Rheum 41:2014–2021CrossRefPubMed

13.

Suda T, Nakamura I, Jimi E, Takahashi N (1997) Regulation of osteoclast function. J Bone Miner Res 12:869–879PubMedCrossRef

14.

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclast genesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602PubMedCrossRef

15.

Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R (1995) Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 54:801–816PubMed

16.

Verstraeten A, Dequeker J (1986) Vertebral and peripheral bone mineral content and fracture incidence in post-menopausal patients with rheumatoid arthritis: effct of low dose corticosteroids. Ann Rheum Dis 45:852–857PubMed

17.

Laan RF, van Riel PL, van Erning LJ, Lemmens JA, Ruijs SH, van de Putte LB (1992) Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy. Br J Rheumatol 31:91–96PubMedCrossRef

18.

Piet G, Jan D, Johan V, Rita S, Steven B, Jo J, Jo N, Jef R (1998) Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomized placebo controlled study. Ann Rheum Dis 57:724–727PubMedCrossRef

19.

Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA (1989) Clinical, biochemical, and radiographic effects of aminohydroxypropylidine bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 48:396–399PubMed

20.

Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Valkema R, Westedt ML, Landman JO, Pauwels EK, Breedveld FC (1996) Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double blind trial. Arthritis Rheum 39:396–402PubMedCrossRef

21.

Heikki V, Leena L, Marja-Kaisa K, Jami M, Claes F, Juha R, Yrjo TK (2003) Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol 30:468–473PubMed

22.

Hirano K (2003) Effects of bisphosphonate on the inflammation. Clin Calcium 2:128–133

23.

Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R (1995) Effect of clodronate on established collagen-induced arthritis in rats. Inflamm Res 44:258–263CrossRefPubMed

24.

Tanaka T, Nakayama T, Katsumata T (2001) Therapeutic agent for osteoporosis possessing analgesic effect. Bio Clinica 16:237–241CrossRef

25.

Serre CM, Farlay D, Delmas PD, Chenu C (1999) Evidence for a dense and intimate innervation of bone tissue, including glutamate-containing fibers. Bone 25:623–629CrossRefPubMed

26.

Stein C, Millan MJ, Yassouridis A, Herz A (1988) Antinocicetive effects of μ-κ-agonists in inflammation are enhanced by a peripheral opioid receptor-specific mechanism. Eur J Pharmacol 155:255–264CrossRefPubMed

27.

Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Basbaum AI (1984) Intraneuronal substance P contributes to the severity of experimental arthritis. Science 226:547–549PubMedCrossRef

28.

Nagashima M, Tanaka H, Takahashi H, Tachihara A, Tanaka K, Ishiwata T, Asano G, Yoshino S (2002) Study of the mechanism involved angiogenesis and synovical cell proliferation in human synovial tissues of patients with rheumatoid arthritis using SCID mice. Lab Invest 82:981–988PubMed

Title: Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models
Authors: Kaname Yamamoto
Shinichi Yoshino
Goukei Shue
Masakazu Nagashima
Publication date: 01-05-2006
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 7/2006
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-005-0042-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2006

Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide

The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease

Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns

Psychosocial aspects of Turkish mothers of children with juvenile idiopathic arthritis

The phenotype–genotype correlations of FMF patients: a single center study

Factorial validity and norm data comparison of the Short Form 12 in patients with inflammatory-rheumatic disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page